search
Back to results

The RODEO Micro Mapping Catheter in Cryoablation Procedures (RODEO-MaPS)

Primary Purpose

Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Rodeo Micro Mapping Catheter
Sponsored by
afreeze GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Atrial Fibrillation focused on measuring Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Cryoablation, Cryosurgery, Mapping Catheter

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years and legal capacity.
  • Atrial fibrillation, diagnosed in accordance with the guidelines of the ESC (version 2016) - permanent AF excluded.
  • Patient planned for a pulmonary vein isolation catheter ablation procedure using cryoenergy and suitable for treatment according to the respective instructions for use (IFU).
  • Signed and dated informed consent documented by the patient, indicating that the patient has been informed of all the pertinent aspects of the trial prior to study enrolment (patient has received a copy of the ICF).

Exclusion Criteria:

  • Indication that the vascular system is not accessible through the left or right groin.
  • Indication that a transseptal puncture cannot be performed.
  • Any previous ablation or surgery due to AF.
  • Important comorbidities such as cardiovascular events within six months of enrolment or high-risk surgical patients.
  • Left atrial diameter > 50 mm in the short axis.
  • Advanced structural heart disease including

    • moderate-to-severe valvular stenosis or regurgitation,
    • previous valve replacement or valve repair,
    • congenital heart disease,
    • left ventricular ejection fraction < 45% during sinus rhythm,
    • congestive heart failure NYHA III or IV,
    • coronary artery bypass graft surgery within the last 3 months.
  • Permanent pacemaker.
  • Pregnant women at the time of the cryoablation procedure.
  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the Informed Consent Form.
  • Participation in interventional trials for cardiovascular devices or drugs.

Sites / Locations

  • Medizinische Universität InnsbruckRecruiting
  • Marienhaus Klinikum St. Elisabeth Neuwied

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Rodeo Micro Mapping Catheter

Arm Description

Determination of pulmonary vein isoation during cryoablation procedure

Outcomes

Primary Outcome Measures

Feasibility of the Rodeo Micro Mapping Catheter
Percentage of pulmonary veins with diagnostically conclusive signals measured with the RODEO Micro Mapping Catheter.
Positioning of the Rodeo Micro Mapping Catheter
Percentage of pulmonary veins where positioning of the cryoablation catheter with the Rodeo Micro Mapping Catheter as guidewire was possible

Secondary Outcome Measures

Safety of the Rodeo Micro Mapping Catheter.
Percentage of adverse events related to the Rodeo Micro Mapping Catheter
Efficacy of the Rodeo Micro Mapping Catheter
Percentage of successfully isolated pulmonary veins
Real-time pulmonary vein isolation
Time from beginning of the freeze to conduction blockade (time to effect)
Procedural safety
Procedure-related adverse events
Total procedure time
Total procedure time defined from introduction of the transseptal sheath until removal of the transseptal sheath
Cryoablation catheter procedure time
Cryoablation catheter procedure time defined from introduction of the cryoablation catheter into the left atrium until removal of the cryoablation catheter from the left atrium after termination of the last cryo-application
Total fluoroscopy time and dose
Total fluoroscopy time and dose defined from introduction of the transseptal sheath until removal of the transseptal sheath
Cryoablation catheter fluoroscopy time and dose
Cryoablation catheter fluoroscopy time and dose defined from introduction of the cryoablation catheter into the left atrium until removal of the cryoablation catheter from the left atrium after termination of the last cryo-application

Full Information

First Posted
April 12, 2021
Last Updated
July 20, 2022
Sponsor
afreeze GmbH
Collaborators
Competence Center for Medical Devices GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT04845750
Brief Title
The RODEO Micro Mapping Catheter in Cryoablation Procedures
Acronym
RODEO-MaPS
Official Title
The RODEO Micro Mapping Catheter in Cryoablation Procedures - A Feasibility Study
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 14, 2021 (Actual)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
January 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
afreeze GmbH
Collaborators
Competence Center for Medical Devices GmbH

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This clinical investigation evaluates the feasibility of the Rodeo Micro Mapping Catheter in combination with cryoablation ssystem (sclerotherapy of muscle tissue of the heart by freezing) in patients with atrial fibrillation (permanent atrial fibrillation excepted). Further aims of this study are the evaluation of safety of the device and average procedure and fluoroscopy times.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Arrhythmias, Cardiac, Cardiovascular Diseases, Heart Diseases
Keywords
Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Cryoablation, Cryosurgery, Mapping Catheter

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
37 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Rodeo Micro Mapping Catheter
Arm Type
Experimental
Arm Description
Determination of pulmonary vein isoation during cryoablation procedure
Intervention Type
Device
Intervention Name(s)
Rodeo Micro Mapping Catheter
Intervention Description
The Rodeo Micro Mapping Catheter is used during cryoablation of atrial fibrillation patients for determination of pulmonary vein isolation
Primary Outcome Measure Information:
Title
Feasibility of the Rodeo Micro Mapping Catheter
Description
Percentage of pulmonary veins with diagnostically conclusive signals measured with the RODEO Micro Mapping Catheter.
Time Frame
1-3 hours
Title
Positioning of the Rodeo Micro Mapping Catheter
Description
Percentage of pulmonary veins where positioning of the cryoablation catheter with the Rodeo Micro Mapping Catheter as guidewire was possible
Time Frame
1-3 hours
Secondary Outcome Measure Information:
Title
Safety of the Rodeo Micro Mapping Catheter.
Description
Percentage of adverse events related to the Rodeo Micro Mapping Catheter
Time Frame
1-3 day follow-up period
Title
Efficacy of the Rodeo Micro Mapping Catheter
Description
Percentage of successfully isolated pulmonary veins
Time Frame
1-3 hours
Title
Real-time pulmonary vein isolation
Description
Time from beginning of the freeze to conduction blockade (time to effect)
Time Frame
1-3 hours
Title
Procedural safety
Description
Procedure-related adverse events
Time Frame
1-3 hours
Title
Total procedure time
Description
Total procedure time defined from introduction of the transseptal sheath until removal of the transseptal sheath
Time Frame
1-3 hours
Title
Cryoablation catheter procedure time
Description
Cryoablation catheter procedure time defined from introduction of the cryoablation catheter into the left atrium until removal of the cryoablation catheter from the left atrium after termination of the last cryo-application
Time Frame
1-3 hours
Title
Total fluoroscopy time and dose
Description
Total fluoroscopy time and dose defined from introduction of the transseptal sheath until removal of the transseptal sheath
Time Frame
1-3 hours
Title
Cryoablation catheter fluoroscopy time and dose
Description
Cryoablation catheter fluoroscopy time and dose defined from introduction of the cryoablation catheter into the left atrium until removal of the cryoablation catheter from the left atrium after termination of the last cryo-application
Time Frame
1-3 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years and legal capacity. Atrial fibrillation, diagnosed in accordance with the guidelines of the ESC (version 2016) - permanent AF excluded. Patient planned for a pulmonary vein isolation catheter ablation procedure using cryoenergy and suitable for treatment according to the respective instructions for use (IFU). Signed and dated informed consent documented by the patient, indicating that the patient has been informed of all the pertinent aspects of the trial prior to study enrolment (patient has received a copy of the ICF). Exclusion Criteria: Indication that the vascular system is not accessible through the left or right groin. Indication that a transseptal puncture cannot be performed. Any previous ablation or surgery due to AF. Important comorbidities such as cardiovascular events within six months of enrolment or high-risk surgical patients. Left atrial diameter > 50 mm in the short axis. Advanced structural heart disease including moderate-to-severe valvular stenosis or regurgitation, previous valve replacement or valve repair, congenital heart disease, left ventricular ejection fraction < 45% during sinus rhythm, congestive heart failure NYHA III or IV, coronary artery bypass graft surgery within the last 3 months. Permanent pacemaker. Pregnant women at the time of the cryoablation procedure. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the Informed Consent Form. Participation in interventional trials for cardiovascular devices or drugs.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Andreas Kaiser, PhD
Phone
+43 (0)699 11073109
Email
andreas.kaiser@afreeze.com
First Name & Middle Initial & Last Name or Official Title & Degree
afreeze GmbH
Phone
+43 (0)512 209012
Ext
0
Email
clinical.research@afreeze.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Florian Hintringer, MD
Organizational Affiliation
Medizinische Universität Innsbruck
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medizinische Universität Innsbruck
City
Innsbruck
State/Province
Tirol
ZIP/Postal Code
6020
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Florian Hintringer, MD
Facility Name
Marienhaus Klinikum St. Elisabeth Neuwied
City
Neuwied
State/Province
Rheinland-Pfalz
ZIP/Postal Code
56564
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Burkhard Hügl, MD

12. IPD Sharing Statement

Learn more about this trial

The RODEO Micro Mapping Catheter in Cryoablation Procedures

We'll reach out to this number within 24 hrs